Close

MyoKardia (MYOK) Announces Receipt of Orphan Drug Designation for MYK-461 for Treatment of Symptomatic oHCM

May 2, 2016 8:25 AM EDT Send to a Friend
MyoKardia, Inc. (Nasdaq: MYOK), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login